Search clinical trials for: splenic marginal zone lymphoma

Total 11913 results

Scotland and Newcastle Lymphoma Group

Unknown

Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom
Taunton and Somerset Hospital

Completed

Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma

Lymphoma

Australia, United Kingdom
National Cancer Institute (NCI)

Completed

Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma

United States
Clatterbridge Centre for Oncology

Unknown

Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia

Lymphoma | Small Intestine Cancer | Neutropenia | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Psychosocial Effects of Cancer and Its Treatment

United Kingdom
University of California, Davis

Unknown

Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
Lymphoma Study Association

Unknown

Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom, France
Cancer Research Campaign Clinical Trials Centre

Completed

Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma

Lymphoma | Testicular Germ Cell Tumor | Breast Cancer | Small Intestine Cancer | Ovarian Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Infection | Extragonadal Germ Cell Tumor

United Kingdom
Astex Pharmaceuticals, Inc.

Terminated

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

Lymphoma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Boston Medical Center

Completed

Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

Lymphoma | Leukemia | Small Intestine Cancer | Precancerous Condition

United States, Italy, Germany, France
Amgen
National Cancer Institute (NCI)

Completed

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

Sarcoma | Lymphoma | Small Intestine Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Vion Pharmaceuticals

Completed

VNP40101M in Treating Patients With Advanced or Metastatic Cancer

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Vion Pharmaceuticals

Completed

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy

Lymphoma | Leukemia | Anemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center

Completed

Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Radiation Toxicity | Oral Complications | Drug/Agent Toxicity by Tissue/Organ

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

Lymphoma | Leukemia | Oral Complications

United States
Beth Israel Deaconess Medical Center

Completed

Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders

Lymphoma | Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Lung Cancer | Prostate Cancer | Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas

Lymphoma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Lymphoma | Leukemia | Small Intestine Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma

Lymphoma | Small Intestine Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation

Depression | Pain | Lymphoma | Myelodysplastic Syndromes | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Anxiety Disorder

United States
National Cancer Institute (NCI)

Completed

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Withdrawn

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Pyroxamide in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
National Cancer Institute (NCI)

Terminated

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease (CBV)

Lymphoma

United States
National Cancer Institute (NCI)

Completed

Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Biogen

Terminated

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

Lymphoma

United States
London Health Sciences Centre

Completed

Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

Lymphoma | Kidney Cancer | Breast Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Endometrial Cancer

Canada
BioCryst Pharmaceuticals

Completed

BCX-1777 in Treating Patients With Refractory Cancer

Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

Lymphoma

United States
National Cancer Institute (NCI)

Terminated

PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse... and other conditions

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

Cancer

United States
Roswell Park Cancer Institute

Completed

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States
Martin, Paul
National Cancer Institute (NCI)

Terminated

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

Cancer

United States, Canada
National Cancer Institute (NCI)

Completed

PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Novartis Pharmaceuticals

Completed

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Lymphoma | Breast Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Melanoma (Skin) | Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome

United States
University of Kentucky

Completed

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

Sarcoma | Lymphoma | Leukemia | Breast Cancer | Ovarian Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Neuroblastoma

United States

Search clinical trials for: splenic marginal zone lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations